Gossamer Bio, Inc. (GOSS)
| Market Cap | 56.76M -89.2% |
| Revenue (ttm) | 53.29M +32.4% |
| Net Income | -125.22M |
| EPS | -51.97 |
| Shares Out | 6.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,209 |
| Open | 9.54 |
| Previous Close | 9.31 |
| Day's Range | 8.99 - 9.54 |
| 52-Week Range | 8.99 - 309.60 |
| Beta | 2.21 |
| Analysts | Buy |
| Price Target | 82.48 (+788.79%) |
| Est. Earnings | Nov 4, 2026 |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp... [Read more]
Financial Performance
In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price target is $82.48, which is an increase of 788.79% from the latest price.
News
Gossamer Bio initiated with a Buy at Chardan
Chardan analyst Andreas Argyrides initiated coverage of Gossamer Bio (GOSS) with a Buy rating and $160 price target The firm says the bull case centers around FDA approval of seralutinib.
Gossamer Bio submits New Drug Application to FDA for seralutinib
Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the treatment of PAH. This is…
Gossamer Bio submits New Drug Application to FDA for seralutinib
Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the treatment of PAH. This is…
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of se...
Gossamer Bio target adjusted to $90 for split at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio adjusted the firm’s price target on Gossamer Bio (GOSS) to $90 from $2 and keeps a Buy rating on the shares. The analyst updated the…
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of...
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on September 16, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio announces effectiveness of 1-for-80 reverse stock split
Gossamer Bio (GOSS) announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware…
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of se...
Gossamer Bio trading halted, news pending
19:50 EDT Gossamer Bio (GOSS) trading halted, news pending
Gossamer Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Positive FDA interactions and updated guidance support the NDA submission for seralutinib, with a broad label expected for WHO Group 1 PH. Strong clinical support, robust efficacy in CTD-associated PAH, and a solid commercial plan position the drug for rapid uptake if approved.
Gossamer Bio announces 1-for-80 reverse stock split
Gossamer Bio (GOSS) announced that its board of directors has selected a 1-for-80 reverse stock split of the Company’s common stock and a proportionate reduction in the number of authorized…
Gossamer Bio Announces 1-for-80 Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of se...
Gossamer Bio Slides: Corporate presentation
Gossamer Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Gossamer Bio to Present at Cantor Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of...
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on September 3, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio announces upt to $250M structured private placement
Gossamer Bio (GOSS) entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing expected to provide aggregate gross proceeds of...
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of se...
Gossamer Bio reports Q2 EPS (8c), consensus (12c)
Cash, cash equivalents and marketable securities totaled $57.0 million as of June 30, 2026. Gossamer expects the combination of current cash, cash equivalents and marketable securities will be suffici...
Gossamer Bio price target lowered to $4 from $15 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Gossamer Bio (GOSS) to $4 from $15 and keeps an Overweight rating on the shares. The firm notes the…
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of se...
Gossamer Bio Quarterly report: Q2 2026
Gossamer Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Gossamer Bio Earnings release: Q2 2026
Gossamer Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Gossamer Bio upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gossamer Bio (GOSS) to Outperform from Market Perform with an unchanged $1 price target after the company announced an FDA regulatory update and reacquisition of Seralutinib rights. T...
Gossamer Bio Transcript: Investor update
FDA confirmed review issues for seralutinib's NDA in PAH, supporting a September 2026 submission and potential Q3 2027 approval. Worldwide rights were reacquired, debt was reduced, and launch readiness will resume, with ex-U.S. filings planned. PH-ILD is a key future indication.